This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PKBO Peak Bio (PKBO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Peak Bio Stock (NASDAQ:PKBO) 30 days 90 days 365 days Advanced Chart Get Peak Bio alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.1152-Week Range$0.00▼$0.26Volume66,140 shsAverage Volume8,940 shsMarket Capitalization$520.31 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California. Read More Receive PKBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Peak Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PKBO Stock News HeadlinesAkari Therapeutics announce shareholder approval connected with Peak Bio mergerNovember 9, 2024 | markets.businessinsider.comAkari Therapeutics Plc: Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. MergerNovember 8, 2024 | finanznachrichten.deGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available.July 20 at 2:00 AM | Paradigm Press (Ad)Peak Bio Inc (PKBO)October 19, 2024 | investing.comPeak Bio, Inc. (PKBO)September 28, 2024 | finance.yahoo.comAkari Therapeutics Plc: Rob Bazemore Appointed to the Board of Directors of Akari TherapeuticsSeptember 17, 2024 | finanznachrichten.deWhat Peak 65 Means for My Gen X ClientsAugust 29, 2024 | msn.comAKARI THER.ADR/2000 -,01 (CLA.MU)August 28, 2024 | uk.finance.yahoo.comSee More Headlines PKBO Stock Analysis - Frequently Asked Questions How were Peak Bio's earnings last quarter? Peak Bio, Inc. (NASDAQ:PKBO) announced its quarterly earnings results on Tuesday, November, 12th. The company reported $0.06 earnings per share (EPS) for the quarter. What other stocks do shareholders of Peak Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Peak Bio investors own include Check-Cap (CHEK), Pulmonx (LUNG), Minerva Neurosciences (NERV), Crescent Biopharma (CBIO), Adicet Bio (ACET), Absci (ABSI) and Aeglea BioTherapeutics (AGLE). Company Calendar Last Earnings11/12/2024Today7/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PKBO CIK1834645 Webpeak-bio.com Phone650-549-9103FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.83 million Net MarginsN/A Pretax Margin-4,433.33% Return on EquityN/A Return on Assets-179.31% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.06 Sales & Book Value Annual Sales$370 thousand Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value($0.90) per share Price / Book-0.03Miscellaneous Outstanding Shares23,125,000Free Float18,523,000Market Cap$520.31 thousand OptionableNot Optionable Beta1.75 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:PKBO) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSteve Jobs' Deathbed Secret Finally LeakedLeaked: Jobs’ Final Apple Project Exposed Bloomberg just leaked details of a secret project Steve Jobs set ...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Peak Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Peak Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
